海外の治験の状況「前立腺癌」での検索結果
242件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- A randomized, multi-center study to assess the effect of Darbepoetin alfa (Aranesp®) for the treatment of anemia in patients with advanced hormone independent prostate cancer and anaemia - DANCAPepo
- In an open randomised, multi-center study to identify the haematopoietic response to Aranesp® (Darbepoetin 6,75 mcg/kg) administrated every fourth week compared to standard care of treatment in patients with anaemia due to hormone refractory prostate cancer with progression of skeletal metastases. A haematopoietic response is defined as haemoglobin concentration > 12 g/dl or increase in haemoglobin > 2 g/dl during the treatment phase. MedDRA version: 6.1 Level: PT Classification code 10038444
- Denmark
- 2006-05-19
Authorised
- An Open-Label, Multi-Centre, Extension Study, evaluating the Long-Term Safety and Tolerability of Different Three-Month Degarelix Dosing Regimens, 240 mg (40 mg/mL), 240 mg (60 mg/mL), in Patients with Prostate Cancer. - -
- Prostate cancer patient MedDRA version: 7.0 Level: pr t Classification code 10060862
- Belgium, Finland, Germany, Netherlands, United Kingdom
- 2005-12-19
Authorised
- Phase II Study of Dasatinib (BMS-354825) for Androgen-Deprived Progressive Prostate Cancer + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 2.0 dated 15-Aug-06)
- Advanced prostate cancer
- France, Italy
- 2006-10-27
Authorised
- A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination with Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2) - ASCENT-2
- For the treatment of metastatic androgen independent prostate cancer
- Czech Republic, Germany, Hungary
- 2006-05-15
Authorised
- A PHASE II, MULTICENTRE, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF ZD1839 (IRESSA?) IN COMBINATION WITH CASODEX? IN PATIENTS WITH OPERABLE PROSTATE CANCER
- OPERABLE PROSTATE CANCER br>MedDRA version: 6.1 Level: PT Classification code 10060862
- Italy
- 2004-12-14
Authorised
- Phase II trial: uPAR-PET/CT in prostate cancer patients treated with Radium-223-dichloride
- Metastatic castration resistant prostate cancer br>MedDRA version: 19.0 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
- Denmark
- 2016-08-17
Authorised
- Comparison of efficacy and safety of DCVAC/PCa (therapeutic prostate cancer immunotheraphy) against placebo in men with metastatic prostate cancer eligible for chemotherapy
- metastatic castrate-resistant prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, France, Germany, Hungary, Italy, Latvia, Lithuania, Netherlands, Poland, Portugal, Serbia, Slovakia, Spain, Sweden, United Kingdom, United States
- 2013-04-04
Authorised
- A PHASE IIB TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF ONY-P VACCINES IN THE MANAGEMENT OF PROSTATE CANCER WITHOUT DETECTABLE METASTASES FOLLOWING INITIAL ESCAPE FROM HORMONE TREATMENT - THE TREATMENT OF ADVANCED PROSTATE CANCER USING DISABLED CANCER CELLS AS VACCINES
- Prostate cancer without detectable metastases following initial escape from hormone treatment
- Estonia, Hungary, Latvia, Lithuania, United Kingdom
- 2006-03-31
Authorised
- Assessment of the effects of the specific endothelin-A antagonist ZD4054 on prostate cancer biomarkers in patients with castrate-resistant metastatic disease - ZD4054 in metastatic prostate cancer
- Prostate cancer br>MedDRA version: 9.1 Level: LLT Classification code 10036909 Term: Prostate cancer metastatic
- United Kingdom
- 2009-04-27
Authorised
- A study in male patients with newly diagnosed prostate cancer to assess the accuracy of an imaging tracer at diagnosing prostate cancer, in comparison to standard prostate biopsy. In addition, the study will collect additional data on the tracers safety, look at the possible ability in the tracer detecting cancer spread to nearby bone and look at the tumour uptake of the tracer.
- Prostate cancer (PCA) with high risk of metastasis. MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]
- Austria, Germany, Switzerland
- 2017-04-05
